Navigation Links
Rutgers Business School and the Blanche and Irwin Lerner Center will explore trends and issues facing the biopharmaceutical industry at a healthcare symposium, Tuesday, April 30

NEWARK, N.J., April 23, 2013 /PRNewswire-USNewswire/ -- The Food and Drug Administration is still waiting for pharmaceutical companies to begin submitting the first new medicines in a class of prescription drugs known as biosimilars, according to Rachel Sherman , an official with the agency's Center for Drug Evaluation and Research.


Sherman, who is the center's director of medical policy, will be among the speakers addressing some of the pressing issues and major trends facing the biopharmaceutical industry during Rutgers Business School's annual healthcare symposium on Tuesday, April 30, beginning at 8:30 a.m. 

The symposium is sponsored by the Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management Issues. The center has positioned itself as a source of innovative activities and provocative discussions about the drug manufacturing industry.  

"The primary purpose of the symposium is to have a meaningful dialogue among the researchers and professionals in the bio-pharmaceutical area from around the country and those at Rutgers," said Professor Mahmud Hassan, director of the Lerner Center.

In addition to the FDA's Sherman, featured speakers will include Seyed Mortazavi , president of IMS Health's U.S. operations; Joseph Herring , chairman and CEO of Covance; and Scott Gottlieb,  a resident fellow with the American Enterprise Institute.

John Castellani , president and CEO of Pharmaceutical Research and Manufacturers of America, will offer his perspective on trends in the industry as the symposium's keynote speaker. Castellani leads the trade association, known familiarly as PhRMA, that represents the nation's major pharmaceutical research and biotechnology companies.

The symposium will delve into some of the industry's most pressing issues, including the latest innovations to make clinical trials more cost efficient, the progress of FDA efforts to expedite the development of "breakthrough'' drugs, regulatory crackdowns on the manufacturing of injectable medicines and the status of efforts to supply the nation with new anti-infectives.

Sherman is also expected to provide an update on the widely anticipated introduction of biosimilars, new, slightly modified versions of existing biologic medicines that include many powerful cancer-fighters.

The medicines, which have been available in Europe for nearly five years, were expected to provide U.S. patients with alternatives to the high-priced biologics and to help major pharmaceutical companies boost revenues.

"The agency is committed to moving the science forward as soon as possible," Sherman said in an interview leading up to the symposium, "but to date, the FDA has not received an application."

There are no indications that regulators will be reviewing one of the new medicines within the next 10 months. The progress of their development, Sherman said, sits with the drug makers.

"We are doing everything we can," she said, "not to be the stumbling block, by providing for a clear and transparent pathway."

Rutgers Business School offers one of the top-rated MBA programs in pharmaceutical management, and the Blanche and Irwin Lerner Center has strengthened the school's reputation for providing management training and for producing leading academic research.

The Lerner Center thrives in a state rich with pharmaceutical and healthcare giants such as Johnson & Johnson, Celgene and Merck. The industry remains one of the engines fueling the New Jersey economy.

The concentration of pharmaceutical manufacturing and research in New Jersey helped to spur creation of the center at Rutgers Business School in 2007, and it continues to benefit students graduating with a Rutgers MBA in pharmaceutical management.

Professor Hassan, who is also director of the MBA pharmaceutical management program, said the drug research and manufacturing industry is the largest employer of Rutgers MBA graduates, employing nearly 40 percent of them.

"The growth of this industry not only affects the economy of New Jersey, it affects our MBA program as well," Hassan said.

The healthcare symposium will be held at Rutgers Business School, Newark Campus, 1 Washington Park, Room 118. The event runs from 8:30 a.m. until 1:30 p.m.

In addition to MBA and doctoral students, attendees of the symposium will include biopharmaceutical industry executives and professional as well as Rutgers faculty.

Registration is required to be admitted. To RSVP

SOURCE Rutgers Business School
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. High Return-on-Investment Fueling Demand For Rutgers MBA Program
2. Rutgers Business Schools Pharma Industry Scholars Program offers students distinct advantages to help boost careers in healthcare industry
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
5. Nominations Open for San Francisco Business Times Health Care Heroes Awards
6. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
7. Amendia, Inc. and Medline Industries, Inc. Announce Investment and Strategic Business Alliance
8. eCardios CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc.
9. myMatrixx Names Craig Rollins, Vice President of Ancillary and Business Development
10. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
11. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
Post Your Comments:
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... 26, 2015 ... aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie voor ... ) --> ... ) Uit ... Centrum (LUMC) blijkt ...
(Date:11/26/2015)... 2015 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ... demands kidney transplantation is expected to boost the market growth, ... organ transplantation. --> 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ...
Breaking Medicine Technology:
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent ... and the need to integrate dose form selection in early phase drug development. ... membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings ... with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired ... font, giving users limitless opportunities to stylize and create designs quickly and easily, ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor ... application server to improve system efficiency and reliability. , The new Q-Suite 6 platform ... standards, the system avoids locking itself into a specific piece of software for many ...
Breaking Medicine News(10 mins):